Search review questions

Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation

Repeated need for rapid tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation

Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation

Global outcome Need for rescue drug · patients with psychosis‐induced aggression or agitation

Adverse effects ‐ general ‐ one or more drug‐related adverse effect · patients with psychosis‐induced aggression or agitation

Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation

Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation

Repeated need for tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation

Global state: clinically important response, as defined by individual studies · patients with schizophrenia

Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia

Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia

Service use: number of days hospitalised · patients with schizophrenia

Service use: time to hospitalisation · patients with schizophrenia

Quality of life: clinically important change in general quality of life · patients with schizophrenia

Global state: clinically important response, as defined by individual studies · patients with schizophrenia

Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia

Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia

Adverse effect: clinically important adverse effect ( weight ‐ BMI) · patients with schizophrenia

Service use: number of days hospitalised · patients with schizophrenia

Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia

Service use: time to hospitalisation · patients with schizophrenia

Quality of life: clinically important change in general quality of life · patients with schizophrenia

Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia

Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia

Service use: number of days hospitalised · patients with schizophrenia

Service use: time to hospitalisation · patients with schizophrenia

Quality of life: clinically important change in general quality of life · patients with schizophrenia

Global state: clinically important response, as defined by individual studies · patients with schizophrenia

Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia

Clinically important changes in global state · people who are aggressive secondary to serious mental illness

Aggression ‐ Improved to an important extent · people who are aggressive secondary to serious mental illness

Aggression ‐ deterioration: incidence of violence to self or others · people who are aggressive secondary to serious mental illness

Aggression ‐ changes in aggression as recorded by any other outcomes · people who are aggressive secondary to serious mental illness

Adverse effects ‐ physical adverse effects · people who are aggressive secondary to serious mental illness

Adverse effects ‐ death, suicide or natural causes · people who are aggressive secondary to serious mental illness

Adverse effects ‐ psychological adverse effects · people who are aggressive secondary to serious mental illness

Adherence to Adherence to treatment: taking of medication, attending appointments · psychiatrists and people with schizoaffective disorder or schizophrenia

Patient satisfaction: 1. Satisfaction with treatment: average endpoint score (CSQ‐8, high = good, medium term) · psychiatrists and people with schizoaffective disorder or schizophrenia

Patient satisfaction: 2. Satisfaction with therapeutic relationship: average endpoint score (STAR‐P, high = good, medium term) · psychiatrists and people with schizoaffective disorder or schizophrenia

Mental state: General, Positive and Negative Symptoms: Average endpoint score (PANSS General, Positive, Negative, high = poor, medium term) · psychiatrists and people with schizoaffective disorder or schizophrenia

Global State: clinically important improvement · psychiatrists and people with schizoaffective disorder or schizophrenia

Service Use: hospital admission, days in hospital · psychiatrists and people with schizoaffective disorder or schizophrenia

Quality of Life: clinically important improvement · psychiatrists and people with schizoaffective disorder or schizophrenia

Global or clinical change in constipation (a) as defined by the study Still constipated (no defecation) at 2 days · antipsychotic‐related constipation

Adverse events · antipsychotic‐related constipation

Leaving the study early · antipsychotic‐related constipation

Economic costs · antipsychotic‐related constipation

Global or clinical change in constipation (a) as defined by the study Still constipated (no defecation) at 2 days · antipsychotic‐related constipation

Still constipated (no defecation) at 3 days · antipsychotic‐related constipation

(b) Change in the frequency of defecation · antipsychotic‐related constipation